In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according to results from a retrospective cohort study. Compared with white women, Black women with TNBC were less likely to achieve pCR (OR 0.89, 95% CI 0.83-0.95, […]
Clinical Challenges: Sequencing in Metastatic TNBC
As new treatment options continue to emerge for triple-negative breast cancer (TNBC), sequencing of therapy promises to get ever more complicated. TNBC had been estimated to account for about 15% of all breast cancer diagnoses, but that proportion shrank with the new HER2-low designation, which accounts for approximately one-third of patients diagnosed with TNBC. An […]